Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Zolpidem Clear all
Completed Phase 3 Interventional

Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia

NCT00630175
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
zolpidem-MR (modified release), zolpidem (SL800750), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)

NCT02783729
View directory record Official record
Conditions
Insomnia
Interventions
Lemborexant, Lemborexant-matched placebo, Zolpidem tartrate, Zolpidem-matched placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
60
States / cities
Jasper, Alabama • Glendale, Arizona • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia

NCT00466193
View directory record Official record
Conditions
Insomnia
Interventions
zolpidem tartrate sublingual tablet, Placebo
Drug
Lead sponsor
Transcept Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women

NCT00676026
View directory record Official record
Conditions
Healthy
Interventions
Fluoxetine, Zolpidem, Progesterone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 17, 2026, 5:12 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment

NCT04118387
View directory record Official record
Conditions
Sleep Disordered Breathing, Able Bodied
Interventions
Acetazolamide + supplemental oxygen + PAP therapy, Zolpidem + PAP therapy, Buspirone + PAP therapy
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 17, 2026, 5:12 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study

NCT04273776
View directory record Official record
Conditions
Performance Enhancing Product Use
Interventions
Suvorexant 10 mg, Zolpidem, Placebos
Drug
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 39 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 17, 2026, 5:12 AM EDT
Recruiting Phase 4 Interventional

A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia

NCT07542756
View directory record Official record
Conditions
Insomnia, Insomnia Disorder, Chronic Insomnia, Chronic Insomnia Disorder
Interventions
Sleep Hygiene Education, Melatonin IR, 3 mg, Melatonin IR, 5 mg, Diphenhydramine, 25 mg, Diphenhydramine, 50 mg, Doxepin, 3 mg, Doxepin, 6 mg, Trazodone, 50 mg, Trazodone, 100 mg, Placebo, Zolpidem, 5 mg, Zolpidem, 10 mg
Other · Dietary Supplement · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

NCT03375203
View directory record Official record
Conditions
Insomnia Disorders
Interventions
Placebo, JNJ-42847922, 5 mg, JNJ-42847922, 10 mg, JNJ-42847922, 20 mg, Zolpidem
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia

NCT00227942
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Depression
Interventions
Estrogen Replacement Therapy, Zolpidem, placebo
Drug
Lead sponsor
Hadine Joffe, MD
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 17, 2026, 5:12 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem

NCT00781482
View directory record Official record
Conditions
Healthy
Interventions
eszopiclone, zolpidem, placebo
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years to 35 Years · Male only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers

NCT02353299
View directory record Official record
Conditions
Healthy
Interventions
Silenor 6 mg, zolpidem 10 mg, Placebo
Drug
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
21 Years to 50 Years · Male only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Novi, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

NCT05106153
View directory record Official record
Conditions
Healthy Non-dependent, Recreational Sedative Users, Abuse Potential
Interventions
Suvorexant, Zolpidem, Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers

NCT00716521
View directory record Official record
Conditions
Methodology Study
Interventions
placebo, zolpidem
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 24, 2009 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Not applicable Interventional Results available

The Role of Partial Reinforcement in the Long Term Management of Insomnia

NCT00662155
View directory record Official record
Conditions
Primary Insomnia
Interventions
Zolpidem, Placebos
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 55 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing

NCT00156533
View directory record Official record
Conditions
Insomnia, Primary Insomnia, Psychophysiologic Insomnia
Interventions
Zolpidem, Sugar Pill
Drug
Lead sponsor
University of Rochester
Other
Eligibility
25 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Zolpidem 10 mg Tablets Under Fed Conditions

NCT00779441
View directory record Official record
Conditions
Healthy
Interventions
Zolpidem 10mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2008 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

Improving Sleep Quality in Heart Failure

NCT03307005
View directory record Official record
Conditions
Sleep Disturbance, Heart Failure
Interventions
Zolpidem Tartrate, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 79 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

NCT01463098
View directory record Official record
Conditions
Insomnia
Interventions
E2006 1.0 mg, E2006 2.5 mg, E2006 5.0 mg, E2006 10.0 mg, E2006 25.0 mg, E2006 50.0 mg, E2006 100 mg, E2006 200 mg, Zolpidem 10 mg, E2006 Matched Placebo or Zolpidem Matched Placebo, E2006 Matched Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients

NCT00086281
View directory record Official record
Conditions
Obstructive Sleep Apnea Syndrome
Interventions
Xyrem (X), Zolpidem (Z), Modafinil (M), Placebo (P)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer

NCT00084669
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Sleep Disorders
Interventions
venlafaxine, zolpidem tartrate, management of therapy complications
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2010 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Zolpidem Tartrate Under Fasting Conditions

NCT00601666
View directory record Official record
Conditions
Insomnia
Interventions
Zolpidem
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sleep and Breathing in the General Population - Chemical Stimuli

NCT04720547
View directory record Official record
Conditions
Sleep-disordered Breathing
Interventions
Zolpidem, No Treatment
Drug · Other
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 17, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Hallucinogens and Other Drugs on Mood and Performance

NCT02033707
View directory record Official record
Conditions
Healthy
Interventions
Hallucinogens and psychoactive substances
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 17, 2026, 5:12 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 17, 2026, 5:12 AM EDT